February 12, 2018 / 8:48 AM / 11 days ago

BRIEF-Richter sees over 50 pct Esmya sales fall in 2018 -CEO

Feb 12 (Reuters) - Richter Gedeon Vegyeszeti Gyar Nyrt CEO Gabor Orban tells press conference:

* EXPECTS MORE THAN 50 PERCENT SALES DECLINE OF ITS UTERINE FIBROID MEDICINE ESMYA IN 2018

* RICHTER AIMS TO COOPERATE FULLY WITH EUROPEAN REGULATORS IN PROBE OF ESMYA, NOT CONSIDERING ANY LEGAL COUNTERSTEPS AT THIS POINT

* ESMYA GLOBAL RIGHTS LISTED AMONG COMPANY‘S ASSETS, WILL BE REVALUED DOWNWARDS AND REFLECTED IN AUDITED BALANCE SHEET TO BE PUBLISHED LATER

* ESMYA PROBE MIGHT AFFECT COMPANY VALUE THROUGH OUTLOOK OF U.S. REGULATORY APPROVAL PROCESS, LONG-TERM REVENUE AND EARNINGS OUTLOOK Further company coverage: (Reporting by Marton Dunai)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below